<code id='114A2090E7'></code><style id='114A2090E7'></style>
    • <acronym id='114A2090E7'></acronym>
      <center id='114A2090E7'><center id='114A2090E7'><tfoot id='114A2090E7'></tfoot></center><abbr id='114A2090E7'><dir id='114A2090E7'><tfoot id='114A2090E7'></tfoot><noframes id='114A2090E7'>

    • <optgroup id='114A2090E7'><strike id='114A2090E7'><sup id='114A2090E7'></sup></strike><code id='114A2090E7'></code></optgroup>
        1. <b id='114A2090E7'><label id='114A2090E7'><select id='114A2090E7'><dt id='114A2090E7'><span id='114A2090E7'></span></dt></select></label></b><u id='114A2090E7'></u>
          <i id='114A2090E7'><strike id='114A2090E7'><tt id='114A2090E7'><pre id='114A2090E7'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:3
          Adobe

          By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

          Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

          advertisement

          It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Why Novartis is going to walk from its acquisition of MorphoSys
          Why Novartis is going to walk from its acquisition of MorphoSys

          MollyFerguson/STATNovartissaidMondaythatitintendstobuyMorphoSysforjustunder$3billion.Thedealwillnotc

          read more
          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more

          He's a Nobel laureate. Critics say he was misleading on Covid

          Photoillustration:AlexHogan/STAT;Sourcephoto:AFPviaGettyOnedaylastAugust,astheystruggledtofigureoutw